Drug General Information |
Drug ID |
D01XDV
|
Former ID |
DNC011900
|
Drug Name |
6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H17NO4
|
Canonical SMILES |
COC1=CC=CC=C1OC2=C3C=C(C(=CC3=NC=C2)OC)OC
|
InChI |
1S/C18H17NO4/c1-20-15-6-4-5-7-16(15)23-14-8-9-19-13-11-18(22-3)17(21-2)10-12(13)14/h4-11H,1-3H3
|
InChIKey |
ZTLZYKICAWTOKI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
MAPK signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
PI3K-Akt signaling pathway
|
Focal adhesion
|
Gap junction
|
Regulation of actin cytoskeleton
|
HTLV-I infection
|
Pathways in cancer
|
MicroRNAs in cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Central carbon metabolism in cancer
|
Choline metabolism in cancer
|
PANTHER Pathway
|
Angiogenesis
|
PDGF signaling pathway
|
Pathway Interaction Database
|
Signaling events mediated by PTP1B
|
Beta3 integrin cell surface interactions
|
S1P3 pathway
|
Nectin adhesion pathway
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
PDGFR-beta signaling pathway
|
Validated targets of C-MYC transcriptional repression
|
PDGF receptor signaling network
|
Reactome
|
PIP3 activates AKT signaling
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
RAF/MAP kinase cascade
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
MAPK Signaling Pathway
|
Osteoblast Signaling
|
Focal Adhesion
|
PIP3 activates AKT signaling
|
PDGF Pathway
|
Signaling Pathways in Glioblastoma
|
Signaling by PDGF
|
References |
REF 1 | A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). |